Cytosorbents
CytoSorbents (NASDAQ: CTSO) develops and commercializes proprietary biocompatible polymer-bead hemoadsorption cartridges for blood purification in critical care and cardiac surgery, distributing in 70+ countries and pursuing FDA approval for its DrugSorb-ATR antithrombotic removal system.
- Company typePublic
- Founded2002
- HeadquartersMonmouth Junction, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cytosorbents does
CytoSorbents Corporation is a publicly traded (NASDAQ: CTSO) medical device company that develops and commercializes blood purification technologies built on a proprietary platform of biocompatible, highly porous polymer beads. The beads remove elevated levels of harmful substances from whole blood and other bodily fluids via hemoadsorption (pore capture and surface adsorption), and are deployed in cartridges compatible with standard hospital blood pumps including dialysis, CRRT, ECMO, and heart-lung machines.
The company's core product is CytoSorb, a CE-marked hemoadsorption device sold in over 70 countries and used primarily in critical care (sepsis, septic shock, cytokine storm) and cardiac surgery applications. The portfolio also includes the investigational DrugSorb-ATR antithrombotic removal system (two FDA Breakthrough Device Designations), the HotSwap cartridge exchange system launched at ISICEM 2026, the PuriFi standalone hemoperfusion pump (over 100 units placed internationally), the ECOS-300CY ex vivo organ perfusion system, and VetResQ for veterinary use. Pipeline products include HemoDefend-BGA (universal plasma, DoD-funded), HemoDefend-RBC, CytoSorb-XL, K+ontrol, and ContrastSorb.
CytoSorbents generates revenue through a hybrid commercial model combining a direct sales organization (primarily Germany and select international territories) with an extensive distributor network spanning 70+ countries. FY2025 revenue was $37.1M (+4% YoY) at 71% gross margins, with the distributor channel representing ~44% of revenue and growing 11.4%, while Germany direct sales declined 10% due to a 2025 restructuring. The company is pursuing FDA approval for DrugSorb-ATR in the U.S. and Canada following an August 2025 appeal denial, and is targeting cash flow breakeven in H2 2026 supported by a Q4 2025 ~10% workforce reduction.
Cytosorbents firmographics
Firmographics- Name
- Cytosorbents
- Legal name
- CytoSorbents, Inc.
- Website
- https://cytosorbents.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CytoSorbents (NASDAQ: CTSO) develops and commercializes proprietary biocompatible polymer-bead hemoadsorption cartridges for blood purification in critical care and cardiac surgery, distributing in 70+ countries and pursuing FDA approval for its DrugSorb-ATR antithrombotic removal system.
- Ownership category
- akta.pro rank
Cytosorbents industry classification
Industry- Product category
- Blood Purification Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges) (HLAHAKAH)
- akta.pro secondary industries
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)
Keywords
Where Cytosorbents is headquartered
LocationHeadquarters
- HQ city
- Monmouth Junction
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cytosorbents business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- CytoSorb Device Sales: Revenue generated from sales of CytoSorb and related blood purification devices and cartridges. Full-year 2025 revenue of $37.1 million, up 4% year-over-year. Gross margins of 71% in 2025. Sold in over 70 countries with direct sales in Germany and select territories, and distributor sales globally.
- PuriFi and Pump Sales: Sales of PuriFi hemoperfusion pumps and related accessories. Over 100 pumps placed internationally as of 2025 year-end, expanding the blood purification infrastructure to fuel device and disposables usage.
- VetResQ Veterinary Products: CytoSorb technology designed for veterinary critical-care applications, available in the US market.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
Cytosorbents product offering
Product offeringCore offering
CytoSorbents develops, manufactures, and commercializes blood purification medical devices based on proprietary biocompatible porous polymer bead technology. Its core product CytoSorb is a CE-marked hemoadsorption cartridge that removes cytokines, toxins, bilirubin, myoglobin, and antithrombotic drugs from blood, used in critical care, cardiac surgery, liver failure, and kidney injury. The company also sells the PuriFi hemoperfusion pump, the ECOS-300CY organ perfusion system, and the HotSwap rapid adsorber exchange system, and is developing the DrugSorb-ATR antithrombotic removal system for FDA approval.
Product overview
CytoSorbents is a blood purification technology company offering a portfolio of products based on proprietary biocompatible, highly porous polymer bead technology. The core product CytoSorb (CE-marked in the EU) is complemented by the investigational DrugSorb-ATR device seeking FDA approval for antithrombotic removal. Supporting products include HotSwap (rapid adsorber exchange system), PuriFi (standalone hemoperfusion pump), and ECOS-300CY (ex vivo organ perfusion). The company also develops VetResQ for veterinary applications and has pipeline products including HemoDefend-BGA, HemoDefend-RBC, and CytoSorb-XL. Products work with standard hospital blood pumps including dialysis, CRRT, ECMO, and heart-lung machines.
Differentiator
Problem solved
Functional benefit
Brands
- CytoSorb: CE-mark approved hemoadsorption device for blood purification in critical care and cardiac surgery
- DrugSorb-ATR
- HotSwap
- PuriFi
- ECOS-300CY
- VetResQ
- HemoDefend-BGA
- HemoDefend-RBC
Products and services
- CytoSorb 300 CE-marked blood purification device using biocompatible, highly porous polymer beads that remove toxic substances from blood by hemoadsorption. Used in critical care and cardiac surgery to reduce elevated levels of harmful compounds including cytokines, bilirubin, myoglobin, and drugs such as ticagrelor and rivaroxaban. CE mark approved in the EU with extensions for bilirubin and myoglobin removal.
- DrugSorb-ATR Investigational antithrombotic removal system using equivalent polymer bead technology to CytoSorb, designed to reduce severity of perioperative bleeding in cardiothoracic surgery patients on blood thinners. Holds two FDA Breakthrough Device Designations for ticagrelor removal and DOAC (apixaban/rivaroxaban) removal.
- HotSwap System enabling rapid exchange of CytoSorb adsorbers during critical care treatment, ensuring safe blood return from used devices and supporting delivery of the right therapy dose.
- PuriFi Hemoperfusion Pump Hemoperfusion pump system enabling independent CytoSorb therapy without dependence on other extracorporeal machines such as dialysis, CRRT, ECMO, or heart-lung machines. Over 100 pumps placed internationally as of 2025 year-end.
- ECOS-300CY Organ Perfusion System Ex vivo organ perfusion system working with CytoSorb technology to support management of inflammatory processes during organ preservation and perfusion procedures.
- VetResQ CytoSorb technology adapted for veterinary critical-care applications. Available only in the US through veterinary distribution channels.
Quantifiable outcome
- 300,000+ cumulative treatments delivered globally by end of 2025
- +7 more outcomes
Companies that use Cytosorbents
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
Cytosorbents technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Cytosorbents partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Aferetica SrlcoreRenewed exclusive distribution partnership with Aferetica Srl in Italy during ISICEM 2026, extending collaboration spanning more than a decade. Partnership includes collaboration on Aferetica's PerLife organ perfusion platform. Aferetica serves as exclusive distributor for CytoSorb products in Italy.
- U.S. Department of Defense (U.S. Army Medical Research Acquisition Activity)coreAwarded nearly $2 million grant to develop HemoDefend-BGA adsorber to create universal plasma by removing anti-A and anti-B antibodies from blood plasma. Program includes two-year preclinical animal study to evaluate safety and efficacy before pursuing human trials. Represents strategic partnership for blood safety applications.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
Cytosorbents competitors and assessment
Company assessmentBroad incumbents
- Nikkiso: Nikkiso manufactures CRRT and dialysis machines (Aquamax) for critical care settings and is a significant global competitor in extracorporeal blood purification equipment used alongside hemoadsorption therapies like CytoSorb.
- Baxter International: Baxter manufactures the Prismax CRRT system and dialysis equipment used in ICU settings where CytoSorb is integrated as an add-on cartridge, making Baxter the dominant platform provider whose installed base CytoSorb depends on.
- Asahi Kasei Medical: Asahi Kasei Medical manufactures leukocyte reduction filters, plasma fractionation products, and other blood purification technologies as part of a broader medical device portfolio, providing overlapping blood purification capabilities to hospitals and blood banks.
- B. Braun: B. Braun manufactures CRRT and hemodialysis equipment (Diapact, Dialog+) commonly used in European ICUs where CytoSorb is integrated, sharing the same hospital customer base and clinical workflows.
- Fresenius Medical Care: Fresenius Medical Care is the global leader in dialysis products and CRRT equipment (multiFiltrate, Omni), with installed base in hospitals worldwide where CytoSorb is deployed alongside their blood pumps.
- Terumo BCT: Terumo BCT manufactures blood component processing and cell therapy technologies, with overlapping capabilities in extracorporeal blood handling systems that intersect with CytoSorb's blood purification applications.
- Edwards Lifesciences: Edwards Lifesciences is a leader in cardiac surgery products including heart valves and hemodynamic monitoring, sharing the cardiac surgery customer base where DrugSorb-ATR is deployed for blood thinner removal during CABG procedures.
Direct peers
- Spectral Medical: Spectral Medical develops Toraymyxin, a polymyxin B hemoperfusion cartridge for endotoxin removal in septic shock, directly competing with CytoSorb's sepsis/septic shock indication with a similar blood-purification cartridge business model.
- Jafron Biomedical: Jafron is a leading Chinese manufacturer of hemoadsorption cartridges (HA series) used in critical care for cytokine and toxin removal, offering the most direct global competition to CytoSorb's core hemoadsorption technology.
- ExThera Medical: ExThera Medical manufactures the Seraph 100 Microbind Affinity Blood Filter, a hemoperfusion device that removes bloodborne pathogens, competing in the same extracorporeal blood purification cartridge category as CytoSorb for hospital critical care use.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cytosorbents social profiles
Digital presenceCytosorbents compliance and trust
Trust signalCompliance3 records
Cytosorbents financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cytosorbents leadership team
Management profileNumber of profiles
Profiles8 records
Cytosorbents subsidiaries and ownership
Company hierarchySubsidiaries3 records
Cytosorbents funding detail
Funding detailFunding overview
Funding rounds12 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cytosorbents M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cytosorbents
What does Cytosorbents do?
CytoSorbents develops, manufactures, and commercializes blood purification medical devices based on proprietary biocompatible porous polymer bead technology. Its core product CytoSorb is a CE-marked hemoadsorption cartridge that removes cytokines, toxins, bilirubin, myoglobin, and antithrombotic drugs from blood, used in critical care, cardiac surgery, liver failure, and kidney injury. The company also sells the PuriFi hemoperfusion pump, the ECOS-300CY organ perfusion system, and the HotSwap rapid adsorber exchange system, and is developing the DrugSorb-ATR antithrombotic removal system for FDA approval.
Is Cytosorbents a public or private company?
Cytosorbents is a public company. It is classified as public and is currently operating.
When was Cytosorbents founded?
Cytosorbents was founded in 2002. It employs 101 to 250 people.
Where is Cytosorbents based?
Cytosorbents is headquartered in Monmouth Junction, United States, in the North America region.
How does Cytosorbents make money?
Three revenue lines are on record. CytoSorb Device Sales are the primary driver. The others are puriFi and Pump Sales and vetResQ Veterinary Products.
Who are Cytosorbents's main competitors?
Broad incumbents on record are Nikkiso, Baxter International, Asahi Kasei Medical, B. Braun, Fresenius Medical Care, Terumo BCT and Edwards Lifesciences. Direct peers are Spectral Medical, Jafron Biomedical and ExThera Medical.
Does Cytosorbents have an API?
No public API is recorded for Cytosorbents.
What industry is Cytosorbents in?
Cytosorbents's product category is Blood Purification Medical Devices. Its primary akta.pro industry code is HLAHAKAH, Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges), with a secondary code of HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 334510 and its SIC code is 3841.